Two doses of Pfizer vaccine give 70% protection against Omicron hospitalisation – Reuters
|According to a study released by South Africa's largest private health insurance administrator, Discovery Health, two doses of Pfizer-BioNTech vaccine give 70% protection against Omicron hospitalisation, as reported by Reuters.
Additional takeaways
"Two doses of Pfizer-BioNTech vaccine give 33% protection against infection during current wave."
"Study suggests risk of reinfection during current wave significantly higher than during previous waves."
"Study finds risk of hospitalisation among adults diagnosed with COVID-19 is 29% lower compared to infection in South Africa's first wave, adjusting for vaccination status."
"Study finds children have 20% higher risk of hospital admission with complications relative to the first wave, despite the very low absolute incidence."
"Analysis includes more than 211,000 positive COVID-19 test results, roughly 78,000 of which were attributed to Omicron, over Nov. 15-Dec. 7."
Market reaction
This headline doesn't seem to be having a significant impact on market sentiment. As of writing, the S&P Futures were flat on the day.
Information on these pages contains forward-looking statements that involve risks and uncertainties. Markets and instruments profiled on this page are for informational purposes only and should not in any way come across as a recommendation to buy or sell in these assets. You should do your own thorough research before making any investment decisions. FXStreet does not in any way guarantee that this information is free from mistakes, errors, or material misstatements. It also does not guarantee that this information is of a timely nature. Investing in Open Markets involves a great deal of risk, including the loss of all or a portion of your investment, as well as emotional distress. All risks, losses and costs associated with investing, including total loss of principal, are your responsibility. The views and opinions expressed in this article are those of the authors and do not necessarily reflect the official policy or position of FXStreet nor its advertisers.